Alaina L Kronenberg, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 15212 Michigan Ave, Dearborn, MI 48126 Phone: 313-582-8856 Fax: 313-582-8265 |
Dr. Daniel B Kozlow, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 23874 Kean St # 130, Dearborn, MI 48124 Phone: 313-626-0909 Fax: 135-515-6883 |
Karena Xin Tien, DO Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 |
Don Pham, DO Ophthalmology Medicare: Medicare Enrolled Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-436-2581 |
Hasan B. Hakim, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6425 Schaefer Rd, Dearborn, MI 48126 Phone: 313-581-3888 |
Robert M. Levine, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: Henry Ford Health System, 5500 Auto Club Drive, Dearborn, MI 48126 Phone: 313-562-8000 |
Dr. David Bruce Tukel, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1922 Monroe St, Dearborn, MI 48124 Phone: 313-274-7540 Fax: 313-274-7544 |
News Archive
Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment.
Pharmacyclics, Inc. today announced that it has entered into stock purchase agreements with various institutional investors for the sale of approximately 6,150,000 shares of its common stock in a registered direct offering at $6.51 per share, the closing price on June 15, 2010.
Certain cells from a mother persist in their children's bodies and can provoke an immune response in which the child's body attacks itself, according to Mayo Clinic research published in the current issue of the Journal of Immunology (http://www.jimmunol.org).
Massachusetts General Hospital (MGH) and the Iacocca Foundation announce today the completion of the Phase I BCG clinical trial in type 1 diabetes, as well as the submission of all safety reports to the U.S. Food and Drug Administration (FDA) and the MGH data safety monitoring boards. Plans for the Phase II clinical study, which will continue the investigation of bacillus Calmette-Guerin (BCG) vaccination as a treatment for people with existing type 1 diabetes, are actively underway.
› Verified 2 days ago